On this episode of Stock Movers:
- Keurig Dr Pepper (KDP) shares soared ahead of the New York open after the company announced it now expects fiscal 2025 constant currency net sales growth in a high-single-digit range, revised from a mid-single-digit growth outlook previously. KDP also announced it is raising $7 billion from Apollo and KKR to help finance its acquisition of JDE Peet’s NV, aiming to ease investor concerns about taking on too much debt.
- Carter's (CRI) shares fall ahead of the open after the children’s apparel company reported net sales for the third quarter that missed the average analyst estimate. The company also plans to reduce offices-based roles by about 15% by the end of 2025, and it boosted the amount of stores it plans to close. 
- Avidity Biosciences (RNA) shares rally in premarket trading after Novartis (NOVN) agreed to buy the biotechnology company in a deal valued at $12 billion. It marks the Swiss drugmaker’s biggest acquisition in more than a decade and adds several potential blockbuster treatments as generic competition looms for its current top-sellers.

On this episode of Stock Movers: - Keurig Dr Pepper (KDP) shares soared ahead of the New York open after the company announced it now expects fiscal 2025 constant currency net sales growth in a high-single-digit range, revised from a mid-single-digit growth outlook previously. KDP also announced it is raising $7 billion from Apollo and KKR to help finance its acquisition of JDE Peet&rsquo;s NV, aiming to ease investor concerns about taking on too much debt. - Carter's (CRI) shares fall ahead of the open after the children&rsquo;s apparel company reported net sales for the third quarter that missed the average analyst estimate. The company also plans to reduce offices-based roles by about 15% by the end of 2025, and it boosted the amount of stores it plans to close. - Avidity Biosciences (RNA) shares rally in premarket trading after Novartis (NOVN) agreed to buy the biotechnology company in a deal valued at $12 billion. It marks the Swiss drugmaker&rsquo;s biggest acquisition in more than a decade and adds several potential blockbuster treatments as generic competition looms for its current top-sellers.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Keurig Dr Pepper Soars; Carter's Falls; Avidity Biosciences Rallies

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/4815ad91-8f2b-4804-8cc1-b38300d854e5/transcript

- Nike (NKE) shares got a boost on Wednesday after a filing showed that Apple CEO Tim Cook purchased $2.95 million worth of shares on Dec. 22. Cook is Nike’s lead independent director and served as a director since 2005, according to the company’s website. The filing shows Cook purchased 50,000 Class B common stock at a weighted average price of $58.97.
- Costco (COST) rose after receiving an upgrade for Christmas, as Northcoast Research analyst Charles Cerankosky raised the recommendation on wholesale giant to buy from neutral. His new price target of $1,100 implies a 29% increase from Tuesday's closing price. Investors who followed Cerankosky's recommendation received a 0% return in the past year, compared with a negative 9.5% return on the shares.
- Dynavax (DVAX) popped after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.

- Nike (NKE) shares got a boost on Wednesday after a filing showed that Apple CEO Tim Cook purchased $2.95 million worth of shares on Dec. 22. Cook is Nike&rsquo;s lead independent director and served as a director since 2005, according to the company&rsquo;s website. The filing shows Cook purchased 50,000 Class B common stock at a weighted average price of $58.97. - Costco (COST) rose after receiving an upgrade for Christmas, as Northcoast Research analyst Charles Cerankosky raised the recommendation on wholesale giant to buy from neutral. His new price target of $1,100 implies a 29% increase from Tuesday's closing price. Investors who followed Cerankosky's recommendation received a 0% return in the past year, compared with a negative 9.5% return on the shares. - Dynavax (DVAX) popped after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm&rsquo;s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.

Nike Jumps, Costco Upgraded, Dynavax Soars

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/75459fc1-6a79-4d0a-a10a-b3bd01160eed/transcript

- Intel (INTC) shares fell Wednesday after a report said that Nvidia Corp. halted a test to use Intel’s production process to make advanced chips. Nvidia recently tested the so-called 18A process but stopped moving forward, Reuters reported, citing two unidentified people familiar with the matter. Spokespeople for Nvidia and Intel didn’t immediately respond to requests for comment. An Intel spokesperson told Reuters that the company’s 18A manufacturing technologies are “progressing well.”

- Dynavax (DVAX) soared after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.


- Snowflake (SNOW) dipped after The Information reported that the software company is in talks to buy the closely held Observe Inc. for around $1 billion. Baird writes that such a deal “could make strategic sense” as a way to compete with Databricks, which “has been very acquisitive to expand its platform.”

- Intel (INTC) shares fell Wednesday after a report said that Nvidia Corp. halted a test to use Intel&rsquo;s production process to make advanced chips. Nvidia recently tested the so-called 18A process but stopped moving forward, Reuters reported, citing two unidentified people familiar with the matter. Spokespeople for Nvidia and Intel didn&rsquo;t immediately respond to requests for comment. An Intel spokesperson told Reuters that the company&rsquo;s 18A manufacturing technologies are &ldquo;progressing well.&rdquo;
- Dynavax (DVAX) soared after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm&rsquo;s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.
 - Snowflake (SNOW) dipped after The Information reported that the software company is in talks to buy the closely held Observe Inc. for around $1 billion. Baird writes that such a deal &ldquo;could make strategic sense&rdquo; as a way to compete with Databricks, which &ldquo;has been very acquisitive to expand its platform.&rdquo;

Intel Falls, Dynavax Climbs, Snowflake Slides 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/c21522d4-7ccb-4b82-a3bd-b3bd010651fe/transcript

On this episode of Stock Movers:
- Shares of Intel (INTC) fell in the early session after Reuters reported that Nvidia halted a test that uses the chip manufacturer’s 18A technology to produce its chips. Nvidia recently tested whether it could manufacture its chips using Intel’s 18A production process but stopped moving forward, Reuters reported, citing two people familiar with the matter. Nvidia did not respond to Reuters’ request for comment, while an Intel spokesperson told Reuters the company’s 18A manufacturing technologies are “progressing well.”
- Shares of Dynavax Technologies (DVAX) soared in premarket trading after Sanofi agreed to buy Dynavax for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.
- Shares of Nike (NKE) moved higher ahead of the US market open after a filing shows that Apple CEO Tim Cook purchased $2.95 million worth of shares on December 22nd. Cook is Nike’s lead independent director and served as a director since 2005, according to the company’s website.

On this episode of Stock Movers: - Shares of Intel (INTC) fell in the early session after Reuters reported that Nvidia halted a test that uses the chip manufacturer&rsquo;s 18A technology to produce its chips. Nvidia recently tested whether it could manufacture its chips using Intel&rsquo;s 18A production process but stopped moving forward, Reuters reported, citing two people familiar with the matter. Nvidia did not respond to Reuters&rsquo; request for comment, while an Intel spokesperson told Reuters the company&rsquo;s 18A manufacturing technologies are &ldquo;progressing well.&rdquo; - Shares of Dynavax Technologies (DVAX) soared in premarket trading after Sanofi&nbsp;agreed to buy&nbsp;Dynavax for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm&rsquo;s closing price Tuesday. The&nbsp;statement&nbsp;on Wednesday came minutes after Sanofi said the&nbsp;US Food and Drug Administration&nbsp;had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib. - Shares of Nike (NKE) moved higher ahead of the US market open after a&nbsp;filing&nbsp;shows that Apple CEO&nbsp;Tim Cook&nbsp;purchased $2.95 million worth of shares on December 22nd. Cook is Nike&rsquo;s lead independent director and served as a director since 2005, according to the company&rsquo;s&nbsp;website.

Intel Declines; Dynavax Rallies; Nike Ticks Higher

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/a6444b34-c6cf-4743-b593-b3bd00f24fb6/transcript

Keurig Dr Pepper Soars; Carter's Falls; Avidity Biosciences Rallies

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips